Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Biodesix, Inc. BDSX
$1.54
-$0.16 (-10.09%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
121647240.00000000
-
week52high
3.00
-
week52low
0.96
-
Revenue
38212000
-
P/E TTM
-1
-
Beta
1.46068500
-
EPS
-1.54000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 12 мая 2022 г. |
| Cowen & Co. | Outperform | 20 апр 2022 г. | |
| Morgan Stanley | Equal-Weight | Overweight | 17 ноя 2021 г. |
| Morgan Stanley | Overweight | Overweight | 12 мая 2021 г. |
| Morgan Stanley | Overweight | Overweight | 18 мар 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SCHULER JACK W | A | 20389189 | 10000 | 31 янв 2023 г. |
| SCHULER JACK W | A | 20379189 | 50000 | 27 янв 2023 г. |
| Kennedy Lawrence T. Jr | A | 124998 | 124998 | 03 янв 2023 г. |
| Kennedy Lawrence T. Jr | A | 27408 | 27408 | 03 янв 2023 г. |
| Kennedy Lawrence T. Jr | A | 91463 | 91463 | 03 янв 2023 г. |
| Strobeck Matthew | A | 151930 | 6097 | 03 янв 2023 г. |
| Franchi Jean M. | A | 153150 | 7317 | 03 янв 2023 г. |
| Kayyem Jon Faiz | A | 150711 | 4878 | 03 янв 2023 г. |
| MASSARANY HANY | A | 152540 | 6707 | 03 янв 2023 г. |
| Watts Charles M | A | 150711 | 4878 | 03 янв 2023 г. |
Новостная лента
Biodesix, Inc. (BDSX) Q3 2022 Earnings Call Transcript
Seeking Alpha
06 ноя 2022 г. в 09:53
Biodesix, Inc. (NASDAQ:BDSX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Representatives Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Chris Brinzey - Investor Relations Conference Call Participants Andrew Brackmann - William Blair Max Masucci - Cowen & Company Kyle Mikson - Canaccord Genuine Operator Good day! And thank you for standing by.
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 08:17
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
Business Wire
20 окт 2022 г. в 06:00
BOULDER, Colo.
Biodesix to Participate in Two Upcoming Investor Conferences in September
Business Wire
06 сент 2022 г. в 06:00
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
06 авг 2022 г. в 13:28
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Max Masucci - Cowen Kyle Mikson - Canaccord Operator Good morning. My name is Joanne and I will be your conference operator today.